{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:55:01Z","timestamp":1780534501324,"version":"3.54.1"},"reference-count":83,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1097\/med.0b013e3283469505","type":"journal-article","created":{"date-parts":[[2011,4,14]],"date-time":"2011-04-14T07:57:38Z","timestamp":1302767858000},"page":"224-230","source":"Crossref","is-referenced-by-count":26,"title":["Hormonal consequences and prognosis of chronic heart failure"],"prefix":"10.1097","volume":"18","author":[{"given":"Philipp","family":"Attanasio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Doehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-12-20211004","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1056\/NEJMra021498","article-title":"Heart failure","volume":"348","author":"Jessup","year":"2003","journal-title":"N Engl J Med"},{"key":"R3-12-20211004","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/heart.83.5.596","article-title":"Epidemiology, aetiology and prognosis of heart failure","volume":"83","author":"McMurray","year":"2000","journal-title":"Heart"},{"key":"R4-12-20211004","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1388-9842(00)00141-0","article-title":"More \u2018malignant\u2019 than cancer? Five-year survival following a first admission for heart failure","volume":"3","author":"Stewart","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"R5-12-20211004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13539-010-0002-6","article-title":"Cachexia as a major underestimated and unmet medical need: facts and numbers","volume":"1","author":"von Haehling","year":"2010","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R6-12-20211004","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0140-6736(96)07015-8","article-title":"Wasting as independent risk factor for mortality in chronic heart failure","volume":"349","author":"Anker","year":"1997","journal-title":"Lancet"},{"key":"R7-12-20211004","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s13539-010-0014-2","article-title":"An overview of sarcopenia: facts and numbers on prevalence and clinical impact","volume":"1","author":"von Haehling","year":"2010","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R8-12-20211004","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1161\/01.CIR.85.4.1364","article-title":"Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure","volume":"85","author":"Mancini","year":"1992","journal-title":"Circulation"},{"key":"R9-12-20211004","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/01.hjr.0000124327.85096.a5","article-title":"Functional and morphological skeletal muscle abnormalities correlate with reduced electromyographic activity in chronic heart failure","volume":"11","author":"Schulze","year":"2004","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"R10-12-20211004","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/eurjhf\/hfn004","article-title":"Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants","volume":"11","author":"Jankowska","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"R11-12-20211004","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.jacc.2003.07.016","article-title":"The relationship between cholesterol and survival in patients with chronic heart failure","volume":"42","author":"Rauchhaus","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R12-12-20211004","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1054\/jcaf.2002.0804216","article-title":"Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure","volume":"8","author":"Horwich","year":"2002","journal-title":"J Card Fail"},{"key":"R13-12-20211004","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1042\/bst0311120","article-title":"Molecular mechanisms regulating hormone-sensitive lipase and lipolysis","volume":"31","author":"Holm","year":"2003","journal-title":"Biochem Soc Trans"},{"key":"R14-12-20211004","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.jacc.2007.08.012","article-title":"Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure","volume":"50","author":"von Haehling","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R15-12-20211004","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/euhj.1998.1446","article-title":"Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure","volume":"20","author":"Anker","year":"1999","journal-title":"Eur Heart J"},{"key":"R16-12-20211004","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ncpendmet0247","article-title":"The need for a standardized definition for cachexia in chronic illness","volume":"2","author":"Springer","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"R17-12-20211004","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin Nutr"},{"key":"R18-12-20211004","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1517\/13543784.14.2.163","article-title":"Future prospects of anticytokine therapy in chronic heart failure","volume":"14","author":"von Haehling","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"R19-12-20211004","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/hrt.2002.007005","article-title":"Inflammatory mediators in chronic heart failure: an overview","volume":"90","author":"Anker","year":"2004","journal-title":"Heart"},{"issue":"Suppl","key":"R20-12-20211004","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1507\/endocrj.43.Suppl_S57","article-title":"Metabolic actions of growth hormone in man","volume":"43","author":"Ho","year":"1996","journal-title":"Endocr J"},{"key":"R21-12-20211004","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/eurjhf\/hfq173","article-title":"The growth hormone\/insulin-like growth factor-I system in chronic heart failure and its interaction with adiponectin","volume":"12","author":"Andreassen","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"R22-12-20211004","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1096-6374(03)00038-8","article-title":"Serum levels of insulin-like growth factor I and its binding proteins in health and disease","volume":"13","author":"Juul","year":"2003","journal-title":"Growth Horm IGF Res"},{"key":"R23-12-20211004","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0735-1097(01)01385-7","article-title":"Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone","volume":"38","author":"Anker","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R24-12-20211004","doi-asserted-by":"crossref","first-page":"C138","DOI":"10.1152\/ajpcell.00114.2003","article-title":"Beneficial effects of GH\/IGF-1 on skeletal muscle atrophy and function in experimental heart failure","volume":"286","author":"Dalla Libera","year":"2004","journal-title":"Am J Physiol Cell Physiol"},{"key":"R25-12-20211004","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/eurjhf\/hfq166","article-title":"Insulin-like growth factor axis (insulin-like growth factor-I\/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin","volume":"12","author":"Watanabe","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"R26-12-20211004","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/eurjhf\/hfp044","article-title":"Growth hormone resistance in severe heart failure resolves after cardiac transplantation","volume":"11","author":"Lund","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"R27-12-20211004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1161\/01.CIR.99.1.18","article-title":"Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity","volume":"99","author":"Genth-Zotz","year":"1999","journal-title":"Circulation"},{"key":"R28-12-20211004","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJM199603283341301","article-title":"A preliminary study of growth hormone in the treatment of dilated cardiomyopathy","volume":"334","author":"Fazio","year":"1996","journal-title":"N Engl J Med"},{"key":"R29-12-20211004","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(97)11329-0","article-title":"Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy","volume":"351","author":"Osterziel","year":"1998","journal-title":"Lancet"},{"key":"R30-12-20211004","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/euhj.1998.1123","article-title":"A placebo controlled study of growth hormone in patients with congestive heart failure","volume":"19","author":"Isgaard","year":"1998","journal-title":"Eur Heart J"},{"key":"R31-12-20211004","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1056\/NEJM199909093411102","article-title":"Increased mortality associated with growth hormone treatment in critically ill adults","volume":"341","author":"Takala","year":"1999","journal-title":"N Engl J Med"},{"key":"R32-12-20211004","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJM199603143341107","article-title":"Androgens in men: uses and abuses","volume":"334","author":"Bagatell","year":"1996","journal-title":"N Engl J Med"},{"key":"R33-12-20211004","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1210\/jcem.87.2.8201","article-title":"Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results form the Massachusetts Male Aging Study","volume":"87","author":"Feldman","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R34-12-20211004","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1210\/jc.2005-1227","article-title":"Testosterone, dehydroepiandrosterone, and physical performance in older men: results from the Massachusetts Male Aging Study","volume":"91","author":"O'Donnell","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R35-12-20211004","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/eurjhf\/hfq108","article-title":"Deficiencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure","volume":"12","author":"Jankowska","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"R36-12-20211004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4088\/JCP.v66n0102","article-title":"Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity","volume":"66","author":"Shores","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R37-12-20211004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1378\/chest.124.1.83","article-title":"Catabolic\/anabolic balance and muscle wasting in patients with COPD","volume":"124","author":"Debigar\u00e9","year":"2003","journal-title":"Chest"},{"key":"R38-12-20211004","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ecl.2007.03.014","article-title":"Male hypogonadism in systemic disease","volume":"36","author":"Kalyani","year":"2007","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R39-12-20211004","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1161\/CIRCULATIONAHA.106.649426","article-title":"Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival","volume":"114","author":"Jankowska","year":"2006","journal-title":"Circulation"},{"key":"R40-12-20211004","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cardfail.2008.12.011","article-title":"Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure","volume":"15","author":"Jankowska","year":"2009","journal-title":"J Card Fail"},{"key":"R41-12-20211004","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2009.04.078","article-title":"Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study","volume":"54","author":"Caminiti","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R43-12-20211004","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/jama.2009.639","article-title":"Circulating estradiol and mortality in men with systolic chronic heart failure","volume":"301","author":"Jankowska","year":"2009","journal-title":"JAMA"},{"key":"R44-12-20211004","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/jama.283.6.763","article-title":"Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels","volume":"283","author":"Bhasin","year":"2000","journal-title":"JAMA"},{"key":"R45-12-20211004","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1378\/chest.122.2.421","article-title":"Reversal of COPD-associated weight loss using the anabolic agent oxandrolone","volume":"122","author":"Yeh","year":"2002","journal-title":"Chest"},{"key":"R46-12-20211004","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/hrt.2009.181065","article-title":"Low circulating androgens and mortality risk in heart failure","volume":"96","author":"G\u00fcder","year":"2010","journal-title":"Heart"},{"key":"R48-12-20211004","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/039463200501800203","article-title":"The regulation of feeding: a cross talk between peripheral and central signalling","volume":"18","author":"Brunetti","year":"2005","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R49-12-20211004","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1210\/endo.141.11.7757","article-title":"Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans","volume":"141","author":"Date","year":"2000","journal-title":"Endocrinology"},{"key":"R50-12-20211004","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2337\/diabetes.51.1.124","article-title":"Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion","volume":"51","author":"Date","year":"2002","journal-title":"Diabetes"},{"key":"R51-12-20211004","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0014-5793(00)02308-5","article-title":"Kidney produces a novel acylated peptide, ghrelin","volume":"486","author":"Mori","year":"2000","journal-title":"FEBS Lett"},{"key":"R52-12-20211004","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1210\/endo.142.2.7987","article-title":"Ghrelin, a novel placental-derived hormone","volume":"142","author":"Gualillo","year":"2001","journal-title":"Endocrinology"},{"key":"R53-12-20211004","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cardiores.2004.01.024","article-title":"Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes","volume":"62","author":"Iglesias","year":"2004","journal-title":"Cardiovasc Res"},{"key":"R54-12-20211004","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature"},{"key":"R55-12-20211004","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.2337\/diabetes.50.11.2540","article-title":"Ghrelin causes hyperphagia and obesity in rats","volume":"50","author":"Wren","year":"2001","journal-title":"Diabetes"},{"key":"R56-12-20211004","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0304-3940(03)00294-5","article-title":"Growth hormone secretagogue receptor expression in the cells of the stomach-projected afferent nerve in the rat nodose ganglion","volume":"342","author":"Sakata","year":"2003","journal-title":"Neurosci Lett"},{"key":"R57-12-20211004","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1161\/hc4201.097836","article-title":"Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic\/catabolic factors","volume":"104","author":"Nagaya","year":"2001","journal-title":"Circulation"},{"key":"R58-12-20211004","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/eurjhf\/hfp088","article-title":"Ghrelin resistance occurs in severe heart failure and resolves after heart transplantation","volume":"11","author":"Lund","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"R59-12-20211004","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0091-3022(03)00014-1","article-title":"Nutritional status in the neuroendocrine control of growth hormone secretion: the model of anorexia nervosa","volume":"24","author":"Scacchi","year":"2003","journal-title":"Front Neuroendocrinol"},{"key":"R60-12-20211004","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.peptides.2010.08.019","article-title":"Altered myocardial expression of ghrelin and its receptor (GHSR-1a) in patients with severe heart failure","volume":"31","author":"Beiras-Fernandez","year":"2010","journal-title":"Peptides"},{"key":"R61-12-20211004","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13539-010-0011-5","article-title":"Ghrelin for cachexia","volume":"1","author":"Akamizu","year":"2010","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R62-12-20211004","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s13539-010-0012-4","article-title":"Ghrelin and its potential in the treatment of eating\/wasting disorders and cachexia","volume":"1","author":"M\u00fcller","year":"2010","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R63-12-20211004","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1161\/01.CIR.0000149746.62908.BB","article-title":"Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure","volume":"110","author":"Nagaya","year":"2004","journal-title":"Circulation"},{"key":"R64-12-20211004","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/genetics\/163.4.1549","article-title":"Evolutionary, structural and biochemical evidence for a new interaction site of the leptin obesity protein","volume":"163","author":"Gaucher","year":"2003","journal-title":"Genetics"},{"key":"R65-12-20211004","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/sj.ijo.0802142","article-title":"Leptin: a review of its peripheral actions and interactions","volume":"26","author":"Margetic","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"R66-12-20211004","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/35078085","article-title":"Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus","volume":"411","author":"Cowley","year":"2001","journal-title":"Nature"},{"key":"R67-12-20211004","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0002-9149(97)00159-8","article-title":"Elevated soluble CD14 receptors and altered cytokines in chronic heart failure","volume":"79","author":"Anker","year":"1997","journal-title":"Am J Cardiol"},{"key":"R68-12-20211004","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1388-9842(02)00177-0","article-title":"Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure","volume":"5","author":"Schulze","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"R69-12-20211004","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1530\/eje.0.1450727","article-title":"Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia","volume":"145","author":"Doehner","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"R70-12-20211004","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.HYP.34.5.1047","article-title":"Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men","volume":"34","author":"Paolisso","year":"1999","journal-title":"Hypertension"},{"key":"R71-12-20211004","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1161\/01.HYP.36.4.501","article-title":"Leptin attenuates cardiac contraction in rat ventricular myocytes: role of NO","volume":"36","author":"Nickola","year":"2000","journal-title":"Hypertension"},{"key":"R72-12-20211004","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCHEARTFAILURE.109.869909","article-title":"Leptin signaling in the failing and mechanically unloaded human heart","volume":"2","author":"McGaffin","year":"2009","journal-title":"Circ Heart Fail"},{"key":"R73-12-20211004","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1253\/circj.CJ-09-0057","article-title":"Adiponectin and cardiovascular disease","volume":"73","author":"Shibata","year":"2009","journal-title":"Circ J"},{"key":"R74-12-20211004","doi-asserted-by":"crossref","first-page":"12152","DOI":"10.1074\/jbc.M311113200","article-title":"Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity","volume":"279","author":"Pajvani","year":"2004","journal-title":"J Biol Chem"},{"key":"R75-12-20211004","doi-asserted-by":"crossref","first-page":"30817","DOI":"10.1074\/jbc.M402367200","article-title":"Insulin\/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity","volume":"279","author":"Tsuchida","year":"2004","journal-title":"J Biol Chem"},{"key":"R76-12-20211004","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0140-6736(03)12255-6","article-title":"Adiponectin and protection against type 2 diabetes mellitus","volume":"361","author":"Spranger","year":"2003","journal-title":"Lancet"},{"key":"R77-12-20211004","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1253\/circj.71.1703","article-title":"Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in nondiabetic men","volume":"71","author":"Otsuka","year":"2007","journal-title":"Circ J"},{"key":"R78-12-20211004","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ijcard.2007.12.002","article-title":"Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: a hospital cohort study","volume":"125","author":"Haugen","year":"2008","journal-title":"Int J Cardiol"},{"key":"R79-12-20211004","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1161\/CIRCULATIONAHA.104.530972","article-title":"Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure","volume":"112","author":"Kistorp","year":"2005","journal-title":"Circulation"},{"key":"R80-12-20211004","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurheartj\/ehm033","article-title":"Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide","volume":"28","author":"McEntegart","year":"2007","journal-title":"Eur Heart J"},{"key":"R81-12-20211004","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/eurjhf\/hfp046","article-title":"Adiponectin is increased in cardiac cachexia irrespective of body mass index","volume":"11","author":"Ara\u00fajo","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"R82-12-20211004","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10741-010-9159-5","article-title":"Is adiponectin a bystander or a mediator in heart failure? The tangled thread of a good-natured adipokine in aging and cardiovascular disease","volume":"15","author":"Shinmura","year":"2010","journal-title":"Heart Fail Rev"},{"key":"R83-12-20211004","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/CIRCHEARTFAILURE.109.885525","article-title":"Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure","volume":"3","author":"Van Berendoncks","year":"2010","journal-title":"Circ Heart Fail"},{"key":"R84-12-20211004","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijcard.2008.12.126","article-title":"High plasma adiponectin is related to low functional capacity in patients with chronic heart failure","volume":"144","author":"Laoutaris","year":"2010","journal-title":"Int J Cardiol"},{"key":"R85-12-20211004","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.jacc.2009.02.038","article-title":"Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure","volume":"53","author":"Tsukamoto","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R86-12-20211004","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13539-010-0013-3","article-title":"Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)","volume":"1","author":"von Haehling","year":"2010","journal-title":"J Cachexia Sarcopenia Muscle"}],"container-title":["Current Opinion in Endocrinology, Diabetes & Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01266029-201106000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T01:04:59Z","timestamp":1633309499000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01266029-201106000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/med.0b013e3283469505","relation":{},"ISSN":["1752-296X"],"issn-type":[{"value":"1752-296X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}